The current project will focus on five main aims:
1. integration of multiplexed cutting-edge sequencing approaches to determine the effect of all tested drug combinations in detail
2. identification of biomarkers that can predict therapy outcome
3. use of microscopic tumor slices rather than less physiological cell suspensions
4. upscaling and simplification of the microfluidic technology to enable routine use by non-specialized staff in the clinic or at third party diagnostic laboratories
5. determining the clinical benefit of the 2nd-generation platform